Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis

Sitryx Therapeutics announced completion of enrollment in its Phase 1b clinical trial of SYX-5219, a first-in-class oral PKM2 modulator for moderate to severe atopic dermatitis, ahead of schedule. The trial enrolled 50 patients across US and European sites and is expected to readout in Q4 2026. The milestone follows positive Phase 1a data showing safety and immunomodulation of type 2 inflammation.